论文部分内容阅读
目的 :比较头孢他美酯与头孢克肟治疗急性细菌性感染的安全性、有效性。方法 :多中心随机对照开放临床试验 ,头孢他美酯组 98例 (男性 4 3例 ,女性 55例 ,年龄 4 0a±s 13a) ,用头孢他美酯2 50～ 50 0mg ,po ,bid ,头孢克肟组 95例 (男性 4 4例 ,女性 51例 ,年龄 4 2a± 14a) ,用头孢克肟 2 0 0mg ,po ,bid ,疗程均为 7～ 14d。结果 :2组临床总有效率分别为 95%与 94 % ,细菌清除率分别为96%与 94 % ,细菌高度敏感百分率分别为 98%与96% ,不良反应发生率分别为 7%与 6% ,经统计学处理差异均无显著意义 (P >0 .0 5)。结论 :头孢他美酯与头孢克肟治疗急性细菌性感染安全、有效
Objective: To compare the safety and efficacy of cefetamet and cefixime in the treatment of acute bacterial infections. METHODS: A multicenter, randomized controlled clinical trial of ceftazidime was given in 98 patients (43 males and 55 females, age 40a ± s13a) with ceftazidime 250 to 50 mg, po, bid, 95 cases of cefixime group (44 males, 51 females, age 4 2a ± 14a), with cefixime 200 mg, po, bid, treatment for 7 to 14 days. Results: The total effective rates of two groups were 95% and 94% respectively, the bacterial clearance rate was 96% and 94% respectively, the highly sensitive rates of bacteria were 98% and 96%, and the incidences of adverse reactions were 7% and 6% , No statistically significant difference (P> 0.05). Conclusion: Cefetamet and cefixime for the treatment of acute bacterial infections are safe and effective